Abstract
Laboratory and clinical investigations have been carried out on PC-904, a new semisynthetic penicillin, and following results were obtained.
1) PC-904 exhibited a growth inhibitory action widely against Gram-positive cocci and Gram-negative bacilli, and stronger antibacterial activity than ABPC and CER against Enterococcus, Klebsiella, Serratia and P. aeruginosa.
2) PC-904 was ialected intravenously by drip infusion singly as chemotherapeutic drug for the respiratory tracy infections, gallbladder infections and urinary tract infections, then favorable results were obtained in 11 cases (91.6%) out of 12 respiratory tract infections and 1 gallbladder intection, while remarkable effects were obtained in 3 cases (609) out of 5 urinary tract infections.
3) No hematological abnormality was noted but rash was observed in 2 cases.
